Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FinlandBack to Finland

Clinical trials in Oulu – page 2

185 clinical trials in Oulu, Finland across 5 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FinlandOur site in FinlandKliinisetTutkimukset.fi(opens in a new tab)
Oulu at a glance
185
clinical trials
  • Research sites5
Type of trial
Recruitment status
Quick filters

185 trials in Oulu

Open in trial search

Osteosarcoma

Recruiting

Cabozantinib Maintenance Therapy vs Best Supportive Care in Osteosarcoma Patients in Complete Remission or with Residual Disease after First‑Line Chemotherapy

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Institut Gustave Roussy

Ovarian cancer recurrent

Recruiting

Rinatabart Sesutecan plus bevacizumab vs standard care as maintenance for recurrent platinum‑sensitive ovarian cancer after second‑line chemotherapy

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Genmab A/S

Systemic lupus erythematosus

Recruiting

Nipocalimab in Adults with Moderate to Severe Systemic Lupus Erythematosus

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Nipocalimab
  • Sponsor:Janssen Cilag International

Small cell lung cancer

Recruiting

A Study of BI 764532, Atezolizumab, Carboplatin, and Etoposide in Patients With Extensive-Stage Small Cell Lung Cancer

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Boehringer Ingelheim Espana S.A.

Neoplasm malignant

Recruiting

Zongertinib for Cancer in Patients Eligible for Early Access Treatment

InvestigationalNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Zongertinib
  • Sponsor:HUS-Yhtymae

Ovarian cancer

Recruiting

A study of sacituzumab tirumotecan and bevacizumab in patients with newly diagnosed advanced ovarian cancer following first-line platinum-based chemotherapy

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Merck Sharp & Dohme LLC

Endometrial cancer+2

Recruiting

A study comparing Rinatabart Sesutecan to other treatments in patients with endometrial cancer who have previously received platinum-based chemotherapy and PD-L1 therapy

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Paclitaxel
  • Sponsor:Genmab A/S

Acute myeloid leukaemia

Recruiting

A study of bleximenib combined with intensive chemotherapy for adults with newly diagnosed acute myeloid leukemia with specific genetic changes.

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Bleximenib
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

B-cell type acute leukaemia

Recruiting

Study of chemotherapy with blinatumomab and tyrosine kinase inhibitors in newly diagnosed children and young adults with Philadelphia chromosome positive B-cell acute lymphoblastic leukemia

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years
  • Substances:Blinatumomab
  • Sponsor:Universita Degli Studi Di Milano Bicocca

Chronic inflammatory demyelinating polyradiculoneuropathy

Recruiting

A study to test if empasiprubart can improve function and is safe for adults with chronic inflammatory demyelinating polyneuropathy

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Empasiprubart
  • Sponsor:Argenx

Non-small cell lung cancer stage IV

Recruiting

A Study of Amivantamab and Lazertinib for Adults with EGFR-Mutated Advanced or Metastatic Non-Small Cell Lung Cancer

InvestigationalNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Janssen Cilag International

Beta haemolytic streptococcal infection

Recruiting

A Study of Group B Streptococcus 6-Valent Polysaccharide Conjugate Vaccine in Healthy Pregnant Women and Their Infants

Investigational
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years · Healthy volunteers
  • Substances:GROUP B STREPTOCOCCUS CAPSULAR POLYSACCHARIDE IB CONJUGATED TO DIPHTHERIA TOXIN CRM197
  • Sponsor:Pfizer Inc.

Other cities in Finland

The busiest research cities in the country

All 28 cities in Finland

Clinical research in Oulu

What the registry says about research in the country

01 Infectious Disease Prevention

Innovative clinical trials focusing on vaccine development against various infectious diseases, including studies of RSV, influenza, and meningococcal vaccines for different age groups.

  • Respiratory Syncytial Virus (RSV) Prevention
  • Influenza Vaccine Development
  • Meningococcal Disease Protection

Multiple studies evaluating immune responses and safety profiles in both pediatric and elderly populations.

02 Cancer Research

Advanced trials in oncology, with particular focus on prostate cancer and lymphoma treatments, including innovative approaches to central nervous system malignancies.

  • Metastatic Prostate Cancer
  • Primary CNS Lymphoma
  • Follicular Lymphoma

Studies combining chemotherapy with novel therapeutic approaches for improved patient outcomes.

03 Surgical and Emergency Medicine

Research examining surgical interventions and emergency treatments, including studies on appendicitis management and advanced imaging techniques for acute conditions.

  • Acute Appendicitis Treatment
  • Frostbite Therapy
  • Gastric Cancer Surgery

Comparative studies of surgical versus non-surgical approaches in acute medical conditions.

Back to FinlandAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.